Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GENTACIDIN vs AKTOB
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting protein synthesis.
Immunosuppressant; inhibits T-cell activation by binding to cyclophilin and inhibiting calcineurin, thereby blocking IL-2 transcription.
Treatment of serious gram-negative bacterial infections,Combination therapy for enterococcal endocarditis,Brucellosis,Tularemia
Prevention of organ rejection in kidney, liver, and heart transplants,Rheumatoid arthritis,Psoriasis
5-7 mg/kg IV every 24 hours.
Adults: 10 mg orally once daily.
2-3 hours in adults with normal renal function; extended to 24-48 hours in anuria or severe renal impairment, requiring dose adjustment.
Terminal elimination half-life is 8-12 hours; prolonged in renal impairment (up to 20-30 hours in anuria).
Primarily excreted unchanged by glomerular filtration; minimal hepatic metabolism.
Hepatic via CYP3A4 enzyme system; major metabolites include AM1, AM9, and AM4N.
Renal: 95-98% unchanged via glomerular filtration; biliary/fecal: <2%.
Renal: 70-80% unchanged; biliary/fecal: 10-15% as metabolites.
10-20% bound to albumin.
20-30% primarily to albumin.
0.2-0.4 L/kg, indicating distribution primarily in extracellular fluid.
0.25-0.4 L/kg; indicates distribution primarily in extracellular fluid.
IM: 90-100%; topical: negligible systemic absorption (<10%); oral: <1%.
Intramuscular: approximately 90%; oral: not absorbed (0% due to degradation in GI tract).
GFR >60 m L/min: 5-7 mg/kg q24h; GFR 30-59: 3-4 mg/kg q24-48h; GFR 15-29: 2-3 mg/kg q48-72h; GFR <15: 1-2 mg/kg q72-96h or after dialysis.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 5 mg once daily; GFR <15 m L/min or dialysis: 2.5 mg once daily.
No adjustment required for Child-Pugh A, B, or C; monitor levels if severe hepatic impairment.
Child-Pugh A: no adjustment; Child-Pugh B: 5 mg once daily; Child-Pugh C: not recommended.
Neonates: 4-5 mg/kg IV q24h; Infants/Children: 5-7.5 mg/kg IV q24h; adjust per therapeutic drug monitoring.
Not established for children <18 years.
Initiate at lower end (5 mg/kg IV q24h) and adjust based on renal function; monitor serum creatinine and drug levels closely.
No specific dose adjustment; monitor for hypotension and renal function.
WARNING: Nephrotoxicity and ototoxicity, even at therapeutic doses; monitor renal function and hearing. Neurotoxicity may occur. Avoid concurrent use with other nephrotoxic or ototoxic drugs.
Increased risk of lymphomas and other malignancies, particularly of the skin. Increased susceptibility to infections. Cyclosporine can cause nephrotoxicity and hepatotoxicity.
Monitor renal function, serum drug levels, and audiometric tests. Use caution in elderly, dehydrated, or renally impaired patients. Prolonged use may lead to superinfection.
Nephrotoxicity, hepatotoxicity, hypertension, hyperkalemia, neurotoxicity, increased risk of infections and malignancies, anaphylaxis (IV formulation).
Hypersensitivity to gentamicin or any aminoglycoside; myasthenia gravis; history of ototoxicity or nephrotoxicity with prior aminoglycoside use.
Hypersensitivity to cyclosporine or any component of the formulation, abnormal renal function, uncontrolled hypertension, malignancies, concurrent use with PUVA or UVB therapy in psoriasis.
No specific food interactions; maintain adequate hydration to reduce renal risk.
No significant food interactions. Avoid alcohol while taking this medication.
Gentamicin is an aminoglycoside antibiotic. Animal studies have shown evidence of fetal harm (nephrotoxicity, ototoxicity). There are no adequate well-controlled studies in pregnant women. Gentamicin crosses the placenta. Risk cannot be ruled out. The drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. First trimester: Theoretical risk of ototoxicity and nephrotoxicity. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve) and nephrotoxicity, especially with prolonged or high-dose therapy.
First trimester: Limited human data; animal studies show adverse effects at high doses. Avoid unless benefit outweighs risk. Second/third trimester: No documented teratogenicity; monitor for fetal growth restriction and oligohydramnios.
Gentamicin is excreted into human milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.2-0.4. Oral bioavailability in infants is poor, so systemic effects are unlikely. However, due to potential for alteration of infant gut flora and direct effects (e.g., diarrhea, allergic reactions), caution is advised. The American Academy of Pediatrics considers gentamicin compatible with breastfeeding. Use only if clearly needed, and monitor infant for signs of gastrointestinal disturbance.
Not recommended during breastfeeding. M/P ratio unknown; potential infant exposure via milk.
Pregnancy may increase glomerular filtration rate, leading to lower serum concentrations. Gentamicin is primarily renally eliminated. Dose adjustments based on renal function and therapeutic drug monitoring are essential. Increased doses or shortened intervals may be required to maintain therapeutic levels. Monitor peak and trough concentrations closely, adjusting dose and interval to achieve target levels (peak 4-10 μg/m L, trough <2 μg/m L).
No standard dose adjustment; increased clearance in pregnancy may require higher doses; therapeutic drug monitoring advised.
Gentacidin (gentamicin sulfate) is an aminoglycoside antibiotic; monitor peak and trough levels to avoid nephrotoxicity and ototoxicity. Adjust dose in renal impairment. Avoid concurrent use with other nephrotoxic drugs (e.g., NSAIDs, vancomycin).
AKTOB is a beta-lactam antibiotic; monitor for hypersensitivity reactions, especially in patients with penicillin allergy. Adjust dose in renal impairment (Cr Cl <30 m L/min). Administer by slow IV infusion over 3-5 minutes or as directed. Observe for signs of Clostridioides difficile infection.
Complete the full course even if symptoms improve.,Report hearing loss, tinnitus, dizziness, or decreased urine output immediately.,May cause injection site pain; rotate sites if applicable.,Avoid alcohol during therapy.
Complete the full course of therapy even if symptoms improve.,Report any signs of allergic reaction such as rash, itching, or difficulty breathing immediately.,Inform your doctor if you have kidney problems or are on dialysis.,This medication may cause diarrhea; do not treat with anti-diarrheal medications without consulting your doctor.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GENTACIDIN vs AKTOB, answered by our medical review team.
GENTACIDIN is a Aminoglycoside Antibiotic that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting protein synthesis.. AKTOB is a Aminoglycoside Antibiotic (Ophthalmic) that works by Immunosuppressant; inhibits T-cell activation by binding to cyclophilin and inhibiting calcineurin, thereby blocking IL-2 transcription.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GENTACIDIN and AKTOB depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GENTACIDIN is: 5-7 mg/kg IV every 24 hours.. The standard adult dose of AKTOB is: Adults: 10 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GENTACIDIN and AKTOB in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GENTACIDIN is classified as Category C. Gentamicin is an aminoglycoside antibiotic. Animal studies have shown evidence of fetal harm (nephrotoxicity, ototoxicity). There are no adequate well-controlled studies in pregnan. AKTOB is classified as Category C. First trimester: Limited human data; animal studies show adverse effects at high doses. Avoid unless benefit outweighs risk. Second/third trimester: No documented teratogenicity; m. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.